Saracatinib

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameSaracatinib
Drug Alias Name沙拉替尼SaracatinibumSaracatinab塞卡替尼沙卡替尼 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase FYN inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsTyrosine-protein kinase FYNTyrosine-protein kinase SRC
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursAlcohol Drinking +[54] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk LtdNational Jewish Health +[5] 
Inactive CompaniesYale UniversityStanford UniversityUniversity College London +[7] 
Active IndicationsAlzheimer DiseaseIdiopathic Pulmonary FibrosisMyositis Ossificans +[5] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsSolid tumoursAlcohol Drinking +[49] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG